Program
D091
A development code.
Its studies are mostly in Prostatic Hyperplasia, led by Chong Kun Dang Pharmaceutical.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Chong Kun Dang Pharmaceutical | 20 open or running | phase 1since Oct 19, 2023 | Oct 19, 2023 | none ahead |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Oct 19, 2023First study: phase 1 study in Prostatic HyperplasiaFirst studyNCT06110923 · 31 enrolled · South Korea
- Jan 29, 2026Phase 1 study in Prostatic HyperplasiaNCT07404735 · 34 enrolled · South Korea
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 2 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07404735Prostatic Hyperplasia · South Korea | 1 | Completed | Jun 2, 2026 | 34 |
| NCT06110923Prostatic Hyperplasia · South Korea | 1 | Completed | May 10, 2024 | 31 |
How it is read
Names in the registry
- “D091”, 2 entries
Codes read as this program: D091.
Conditions, from the studies’ own filings
- Prostatic Hyperplasia, 2 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.